UNBS5162, an amonafide (naphthalimide) derivative, is a potent antitumor agent that inhibits tumor proliferation, progression and invasiveness. UNBS5162 is a pan-antagonist of CXCL chemokine expression. It appears that UNBS5162 inhibits melanoma progression through inhibition of the AKT/mTOR signaling pathway.
pan-antagonist of CXCL chemokine expression
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Neoplasia (New York, N.Y.), 10(6), 573-586 (2008-06-03)
Several naphthalimides have been evaluated clinically as potential anticancer agents. UNBS3157, a naphthalimide that belongs to the same class as amonafide, was designed to avoid the specific activating metabolism that induces amonafide's hematotoxicity. The current study shows that UNBS3157 rapidly
Experimental and therapeutic medicine, 16(5), 3921-3928 (2018-10-23)
UNBS5162, a naphthalimide derivative, has a strong anticancer effect and low clinical hematological toxicity. UNBS5162 has been shown to have an anticancer effect in numerous cancer types, except triple negative breast cancer (TNBC). To explore this issue, TNBC MDA-MB-231 cells
Cancer management and research, 11, 2339-2348 (2019-04-10)
Human melanoma is a malignant tumor originated from melanocytes with high invasion, metastasis, and poor prognosis. In this study, the effects of naphthalimides UNBS5162 and amonafide on the properties of proliferation and apoptosis in human melanoma cells were confirmed. Cell
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
